Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
Trop-2 is an ideal candidate for targeted therapeutics because it is a transmembrane protein with an extracellular domain overexpressed in a wide variety of tumors, and is upregulated in normal cells. Consequently, several Trop-2-targeted drugs have recently been developed for clinical use, such as...
Enregistré dans:
Auteurs principaux: | Sara Bravaccini, Roberta Maltoni |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/1969c0c6d1fe4cd3bb52879c006c3111 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
par: Giacomo Barchiesi, et autres
Publié: (2021) -
Opportunities for metastatic triple negative breast cancer therapy
par: Inna P. Ganshina, et autres
Publié: (2021) -
Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach
par: Hana Kim, et autres
Publié: (2021) -
Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
par: Inna P. Ganshina, et autres
Publié: (2021) -
Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer
par: Peng Su, et autres
Publié: (2021)